Go Pro
→ Why November 27 Is Quickly Becoming America's Most Important Financial Date in Decades (From Altimetry) (Ad)tc pixel Free HAO Stock Alerts

Haoxi Health Technology (HAO) Financials

Haoxi Health Technology logo
$3.98 +0.73 (+22.31%)
Closing price 04:00 PM Eastern
Extended Trading
$3.92 -0.06 (-1.51%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Haoxi Health Technology

Annual Income Statements for Haoxi Health Technology

This table shows Haoxi Health Technology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.24 0.97 1.29 3.88
Consolidated Net Income / (Loss)		 0.24 0.97 1.29 3.88
Net Income / (Loss) Continuing Operations		 0.24 0.97 1.29 3.88
Total Pre-Tax Income 		0.26 1.19 1.74 4.15
Total Operating Income		 0.27 1.20 1.72 -2.00
Total Gross Profit		 0.65 2.06 2.75 0.93
Total Revenue		 16 28 49 33
Operating Revenue		 16 28 49 33
Total Cost of Revenue		 16 26 46 32
Operating Cost of Revenue		 16 26 46 32
Total Operating Expenses		 0.38 0.87 1.03 2.93
Selling, General & Admin Expense		 0.28 0.81 0.95 2.85
Research & Development Expense		 0.10 0.06 0.08 0.08
Total Other Income / (Expense), net		 -0.01 -0.01 0.02 6.15
Interest & Investment Income		 -0.01 -0.02 0.03 0.32
Other Income / (Expense), net		 0.00 0.02 -0.02 5.83
Income Tax Expense		 0.02 0.22 0.44 0.27
Basic Earnings per Share		 $0.01 $0.87 $1.06 $1.66
Weighted Average Basic Shares Outstanding		 25M 1.10M 1.22M 2.33M
Diluted Earnings per Share		 $0.01 $0.87 $1.06 $1.32
Weighted Average Diluted Shares Outstanding		 25M 1.10M 1.22M 2.40M
Weighted Average Basic & Diluted Shares Outstanding		 - - 32.24M 2.90M

Quarterly Income Statements for Haoxi Health Technology

No quarterly income statements for Haoxi Health Technology are available.

Annual Cash Flow Statements for Haoxi Health Technology

This table details how cash moves in and out of Haoxi Health Technology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 0.24 0.91 5.45 1.96
Net Cash From Operating Activities		 -0.68 -0.87 -0.75 -3.36
Net Cash From Continuing Operating Activities		 -0.68 -0.87 -0.75 -3.36
Net Income / (Loss) Continuing Operations		 0.24 0.97 1.29 3.88
Consolidated Net Income / (Loss)		 0.24 0.97 1.29 3.88
Depreciation Expense		 0.00 0.01 0.01 0.29
Amortization Expense		 - 0.00 0.00 1.00
Non-Cash Adjustments To Reconcile Net Income		 0.35 -2.44 -2.72 -7.23
Changes in Operating Assets and Liabilities, net		 -1.27 0.59 0.67 -1.29
Net Cash From Investing Activities		 -0.01 -0.05 -3.13 -3.58
Net Cash From Continuing Investing Activities		 -0.01 -0.05 -3.13 -3.58
Purchase of Property, Plant & Equipment		 -0.01 -0.05 -0.06 0.00
Acquisitions		 - 0.00 0.00 -2.08
Purchase of Investments		 0.00 0.00 -3.07 -2.50
Other Investing Activities, net		 - - 0.00 1.00
Net Cash From Financing Activities		 0.93 1.80 9.32 8.90
Net Cash From Continuing Financing Activities		 0.93 1.80 9.32 8.90
Repayment of Debt		 -0.86 -0.90 -0.13 -4.09
Issuance of Debt		 1.63 0.71 0.48 2.03
Issuance of Common Equity		 0.16 1.99 8.98 0.00
Other Financing Activities, net		 - - 0.00 11
Cash Interest Paid		 0.00 0.02 0.04 0.04
Cash Income Taxes Paid		 0.01 0.00 0.03 0.01

Quarterly Cash Flow Statements for Haoxi Health Technology

No quarterly cash flow statements for Haoxi Health Technology are available.

Annual Balance Sheets for Haoxi Health Technology

This table presents Haoxi Health Technology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 6/30/2023 6/30/2024 6/30/2025
Total Assets		 4.46 16 22
Total Current Assets		 3.67 15 20
Cash & Equivalents		 1.20 6.66 8.62
Accounts Receivable		 0.01 0.23 0.46
Inventories, net		 2.40 5.17 5.70
Prepaid Expenses		 0.06 3.32 4.83
Plant, Property, & Equipment, net		 0.14 0.13 0.11
Total Noncurrent Assets		 0.65 0.00 1.88
Intangible Assets		 - 0.00 1.80
Other Noncurrent Operating Assets		 0.65 0.00 0.08
Total Liabilities & Shareholders' Equity		 4.46 16 22
Total Liabilities		 2.90 4.23 4.22
Total Current Liabilities		 2.58 3.87 3.89
Short-Term Debt		 0.54 0.83 1.61
Accounts Payable		 0.07 0.76 0.15
Current Deferred Revenue		 1.49 1.19 0.54
Current Deferred & Payable Income Tax Liabilities		 0.33 1.04 1.31
Current Employee Benefit Liabilities		 0.04 0.04 0.03
Other Current Liabilities		 0.11 0.01 0.25
Total Noncurrent Liabilities		 0.32 0.37 0.33
Long-Term Debt		 0.25 0.37 0.33
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.57 11 17
Total Preferred & Common Equity		 1.57 11 17
Total Common Equity		 1.57 11 17
Common Stock		 2.18 11 13
Retained Earnings		 -0.57 0.72 4.60
Accumulated Other Comprehensive Income / (Loss)		 -0.04 -0.04 -0.05

Quarterly Balance Sheets for Haoxi Health Technology

No quarterly balance sheets for Haoxi Health Technology are available.

Annual Metrics And Ratios for Haoxi Health Technology

This table displays calculated financial ratios and metrics derived from Haoxi Health Technology's official financial filings.

Metric 2022 2023 2024 2025
Period end date 6/30/2022 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 0.00 0.00 0.00 0.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00
Growth Metrics		 - - - -
Revenue Growth		 0.00% 74.72% 71.88% -32.39%
EBITDA Growth		 0.00% 348.80% 40.27% 199.31%
EBIT Growth		 0.00% 349.37% 40.37% 125.25%
NOPAT Growth		 0.00% 284.69% 31.22% -246.24%
Net Income Growth		 0.00% 296.49% 33.20% 200.13%
EPS Growth		 0.00% 296.49% 33.20% 24.53%
Operating Cash Flow Growth		 0.00% -29.14% 14.28% -349.20%
Free Cash Flow Firm Growth		 0.00% 0.00% -1,814.26% -99.26%
Invested Capital Growth		 0.00% 0.00% 405.38% 83.92%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - -
Gross Margin		 4.02% 7.30% 5.67% 2.83%
EBITDA Margin		 1.68% 4.32% 3.53% 15.61%
Operating Margin		 1.66% 4.24% 3.54% -6.10%
EBIT Margin		 1.67% 4.29% 3.50% 11.68%
Profit (Net Income) Margin		 1.51% 3.44% 2.66% 11.82%
Tax Burden Percent		 94.22% 81.46% 74.44% 93.47%
Interest Burden Percent		 96.30% 98.27% 102.05% 108.29%
Effective Tax Rate		 5.78% 18.54% 25.56% 6.53%
Return on Invested Capital (ROIC)		 0.00% 169.25% 36.68% -22.63%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 171.37% 36.23% -117.37%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -45.44% -16.56% 49.70%
Return on Equity (ROE)		 0.00% 123.81% 20.12% 27.06%
Cash Return on Invested Capital (CROIC)		 0.00% -30.75% -97.24% -81.75%
Operating Return on Assets (OROA)		 0.00% 27.13% 17.03% 20.65%
Return on Assets (ROA)		 0.00% 21.72% 12.94% 20.90%
Return on Common Equity (ROCE)		 0.00% 123.81% 20.12% 27.06%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.25 0.97 1.28 -1.87
NOPAT Margin		 1.57% 3.45% 2.63% -5.70%
Net Nonoperating Expense Percent (NNEP)		 0.00% -2.12% 0.46% 94.74%
Return On Investment Capital (ROIC_SIMPLE)		 - 41.38% 10.25% -9.68%
Cost of Revenue to Revenue		 95.98% 92.70% 94.33% 97.17%
SG&A Expenses to Revenue		 1.72% 2.86% 1.96% 8.68%
R&D to Revenue		 0.63% 0.21% 0.16% 0.24%
Operating Expenses to Revenue		 2.35% 3.07% 2.13% 8.92%
Earnings before Interest and Taxes (EBIT)		 0.27 1.21 1.70 3.83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.27 1.22 1.71 5.12
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 6.13 28.43 0.00
Price to Tangible Book Value (P/TBV)		 0.00 6.13 28.43 0.00
Price to Revenue (P/Rev)		 0.59 0.34 6.60 0.00
Price to Earnings (P/E)		 39.25 9.90 248.05 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 2.55% 10.10% 0.40% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 7.98 54.14 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.33 6.49 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 7.53 184.08 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 7.58 185.23 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 9.43 246.38 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.50 0.11 0.11
Long-Term Debt to Equity		 0.00 0.16 0.03 0.02
Financial Leverage		 0.00 -0.27 -0.46 -0.42
Leverage Ratio		 0.00 2.85 1.56 1.30
Compound Leverage Factor		 0.00 2.80 1.59 1.40
Debt to Total Capital		 0.00% 33.46% 9.63% 10.05%
Short-Term Debt to Total Capital		 0.00% 22.88% 6.68% 8.33%
Long-Term Debt to Total Capital		 0.00% 10.58% 2.95% 1.73%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 66.54% 90.36% 89.95%
Debt to EBITDA		 0.00 0.65 0.70 0.38
Net Debt to EBITDA		 0.00 -0.34 -3.19 -1.30
Long-Term Debt to EBITDA		 0.00 0.20 0.22 0.07
Debt to NOPAT		 0.00 0.81 0.94 -1.04
Net Debt to NOPAT		 0.00 -0.43 -4.27 3.57
Long-Term Debt to NOPAT		 0.00 0.26 0.29 -0.18
Altman Z-Score		 0.00 9.32 49.84 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.01% 0.01%
Liquidity Ratios		 - - - -
Current Ratio		 0.00 1.43 3.98 5.05
Quick Ratio		 0.00 0.47 1.78 2.34
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -0.18 -3.39 -6.75
Operating Cash Flow to CapEx		 -7,764.56% -1,916.77% -1,350.22% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 6.32 4.86 1.77
Accounts Receivable Turnover		 0.00 3,643.41 413.82 95.50
Inventory Turnover		 0.00 10.88 12.08 5.86
Fixed Asset Turnover		 0.00 196.26 358.64 278.43
Accounts Payable Turnover		 0.00 380.18 110.96 70.06
Days Sales Outstanding (DSO)		 0.00 0.10 0.88 3.82
Days Inventory Outstanding (DIO)		 0.00 33.54 30.22 62.26
Days Payable Outstanding (DPO)		 0.00 0.96 3.29 5.21
Cash Conversion Cycle (CCC)		 0.00 32.68 27.81 60.87
Capital & Investment Metrics		 - - - -
Invested Capital		 0.00 1.15 5.82 11
Invested Capital Turnover		 0.00 49.04 13.92 3.97
Increase / (Decrease) in Invested Capital		 0.00 1.15 4.67 4.88
Enterprise Value (EV)		 0.00 9.18 315 0.00
Market Capitalization		 9.60 9.60 320 0.00
Book Value per Share		 $0.00 $1.42 $9.21 $7.44
Tangible Book Value per Share		 $0.00 $1.42 $9.21 $6.67
Total Capital		 0.00 2.35 12 19
Total Debt		 0.00 0.79 1.20 1.94
Total Long-Term Debt		 0.00 0.25 0.37 0.33
Net Debt		 0.00 -0.42 -5.45 -6.68
Capital Expenditures (CapEx)		 0.01 0.05 0.06 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.43 5.69 8.71
Debt-free Net Working Capital (DFNWC)		 0.00 1.64 12 17
Net Working Capital (NWC)		 0.00 1.10 12 16
Net Nonoperating Expense (NNE)		 0.01 0.00 -0.01 -5.75
Net Nonoperating Obligations (NNO)		 0.00 -0.42 -5.45 -6.68
Total Depreciation and Amortization (D&A)		 0.00 0.01 0.01 1.29
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 1.53% 11.73% 26.55%
Debt-free Net Working Capital to Revenue		 0.00% 5.80% 25.45% 52.82%
Net Working Capital to Revenue		 0.00% 3.89% 23.73% 47.92%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $1.00 $1.66
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 1.22M 2.33M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $1.00 $1.32
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 1.22M 2.40M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.29M 2.90M
Normalized Net Operating Profit after Tax (NOPAT)		 0.25 0.97 1.28 -1.87
Normalized NOPAT Margin		 1.57% 3.45% 2.63% -5.70%
Pre Tax Income Margin		 1.61% 4.22% 3.58% 12.64%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Haoxi Health Technology

No quarterly metrics and ratios for Haoxi Health Technology are available.


Financials Breakdown Chart

Haoxi Health Technology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Haoxi Health Technology's fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

Haoxi Health Technology's net income appears to be on an upward trend, with a most recent value of $3.88 million in 2025, rising from $244.59 thousand in 2022. The previous period was $1.29 million in 2024. View Haoxi Health Technology's forecast to see where analysts expect Haoxi Health Technology to go next.

Haoxi Health Technology's total operating income in 2025 was -$2.00 million, based on the following breakdown:
  • Total Gross Profit: $927.75 thousand
  • Total Operating Expenses: $2.93 million

Over the last 3 years, Haoxi Health Technology's total revenue changed from $16.16 million in 2022 to $32.80 million in 2025, a change of 103.0%.

Haoxi Health Technology's total liabilities were at $4.22 million at the end of 2025, a 0.4% decrease from 2024, and a 45.6% increase since 2023.

In the past 2 years, Haoxi Health Technology's cash and equivalents has ranged from $1.20 million in 2023 to $8.62 million in 2025, and is currently $8.62 million as of their latest financial filing in 2025.

Over the last 3 years, Haoxi Health Technology's book value per share changed from 0.00 in 2022 to 7.44 in 2025, a change of 744.5%.


Related Companies

Financial statements for NASDAQ:HAO last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel